Vergelijking
Goserelin vs. Teduglutid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
65807-02-5
197922-42-2
Molecuulmassa
1269.43 g/mol
3752.13 g/mol
Halfwaardetijd
4.2 h
geen gegevens
Sequentie
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2geen gegevens
Werkingsmechanisme
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
4
2
waarvan bij mensen
4
2
Geregistreerde effecten
3
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
2
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Goserelin and Teduglutid?
- Goserelin is classified as "Onderzoek (overig)", while Teduglutid is classified as "Onderzoek (overig)". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Teduglutid?
- The highest available evidence level is "Humane RCT" for Goserelin and "Humane RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Teduglutid in Germany and the United States?
- Duitsland: Goserelin — Op recept, Teduglutid — Op recept. Verenigde Staten: Goserelin — Op recept, Teduglutid — Op recept. These are factual summaries with source and review date on the individual pages.